

Histophysiology study of interleukin-4 in thyroid cancer patients

Ali Reda Hussein¹, Dhamia Kasim Suker², Sanaa Jameel Thamer², Majid Hameed Alabbod³

¹Ph.D. student, Physiology, Biology Department, College of Sciences, Basrah University, Basrah, Iraq

²Biology Department, College of Sciences, Basrah University, Basrah, Iraq

³Alzahraa College of Medicine, Basrah University, Basrah, Iraq

Introduction. Interleukins have promising prospects in the clinical treatment of cancer. Interleukin-4 (IL-4) is an anti-inflammatory cytokine with an immunosuppressive effect on antitumor activity by immune cells, but the mechanical action of IL-4 in thyroid cancer is unknown. Aim: to investigate the effect of IL-4 expression in thyroid cancer patients. Furthermore, to clarify the association between obesity and thyroid cancer.

Material and methods. The present study was conducted on 115 subjects with thyroid nodules (36 with thyroid cancer and 79 with benign lesions) in Basrah, Iraq, from November 2019 to April 2022. To conduct a histophysiology study of IL-4.

Results. There was a significant difference in serum IL-4 between the thyroid cancer and control subjects. A higher level of serum IL-4 was observed in the Hashimoto thyroiditis group. There was no significant difference in body mass index (BMI) between thyroid cancer and control subjects. The expression of tissue IL-4 in thyroid cancer patients was strong in 8 (22.22%) slides, moderate in 7 slides (19.44%), weak in 8 slides (22.22%), and negative in 13 slides (36.11%), while in the control group, it was strong in 7 (30.44%) slides, moderate in 8 slides (34.79%), weak in 5 slides (21.74%) and negative in 3 slides (13.03%).

Conclusions. These findings indicate that serum levels of IL-4 may help diagnose thyroid cancer and identify patients with active disease who deserve closer medical attention. Furthermore, the secretion of IL-4 was systematic and not localized in thyroid cancer tissues. Obesity was not associated with a prevalence of thyroid cancer.

Key words: thyroid cancer, IL-4, obesity, thyroid gland, histophysiology

Introduction

Cancer is a significant public health problem worldwide [1]. Cancer is a class of disease characterized by the uncontrolled division of cells and the ability of these cells to invade other tissues, either by direct invasion into adjacent tissue or by implantation into distant sites (metastasis) [2, 3]. Thyroid cancer is the most dominant cancer type of the endocrine system [4]; its prevalence has increased dramatically worldwide in recent decades [4–7] as a result of environmental factors, radiation exposure, and the rapid development of available imaging

and tools used for the detection of thyroid nodules [7–9]. Thyroid cancer accounts for approximately 2.3% of all new cancer cases in the U.S. [4]. Furthermore, it accounts for ≤1% of all human malignancies, a relatively rare disease responsible for six deaths per million annually [10]. Thyroid nodules represent the majority of lesions found in 19–68% of randomly selected people, and most benign nodules are without complications [10]. Seven percent of them may have a suspicious nodule for thyroid cancer depending on age, sex, radiation exposure, family history, and other factors [5, 11].

Jak cytować / How to cite:

Hussein AR, Suker DK, Thamer SJ, Alabbod MH. *Histophysiology study of interleukin-4 in thyroid cancer patients*. NOWOTWORY J Oncol 2023; 73: 73–80.

In the Iraqi population, thyroid nodules are common. However, thyroid cancer accounts for 1.7% of these nodules [12], while Mansour et al. [13] found that the prevalence of thyroid cancer was 0.4% (No. = 77) from 17878 patients who presented with thyroid lesions in Basrah province.

Many studies have documented that the overall incidence of thyroid carcinoma has increased more rapidly than that of any other malignancy in recent years, especially in women [14], and many serum interleukins have been medically used as diagnostic and prognostic markers or treatments for various types of diseases especially malignant disease [15, 16]. IL-4 has an essential role in inhibiting growth in many kinds of human cancers, including renal and gastric carcinoma [17]. Although many studies demonstrated that IL-4 and IL-10 are anti-inflammatory cytokines that have the immunosuppressive effect of antitumor activity, allowing tumor cells to escape recognition and attack by the immune system which can lead to cancer cell proliferation and metastasis. The mechanism of action of IL-4 in thyroid cancer is unknown [18–20], so understanding the mechanisms of interleukins in thyroid cancer will provide new targets for immunotherapy of thyroid cancer or finding alternative tools to discriminate thyroid cancer from benign lesions. The overall goal of this work was to investigate the effect of IL-4 expression in the blood serum and tissues of thyroid cancer patients. Furthermore, it aims to clarify the association between obesity and thyroid cancer.

Materials and methods

The study population consisted of 36 patients with thyroid cancer (11 men, 25 women) and 79 with benign thyroid lesions (7 men, 72 women); the mean age of thyroid cancer samples was 36.166 ± 16.84 years, and the mean age of control samples was 40.016 ± 10.519 years. All subjects were undergoing health checkups in Iraq/Basrah province hospitals and medical centers from November 2019 to April 2022. For the immunohistochemistry (IHC) study of IL-4 expression in thyroid cancer patients, all blood samples were collected by collecting 5 ml of peripheral venous blood without anticoagulant and allowed to clot in gel tubes at room temperature to study IL-4 expression in thyroid cancer patients. The IL-4 ELISA kit (catalog No.: E-EL-H0101) by Elabsceince/China (USA brand) was used to determine human IL-4 in blood serum. BMI was determined according to [21].

Fifty-seven paraffin wax-embedded tissues were collected from patients after surgery for both thyroid cancer ($n = 36$) and benign (control) subjects ($n = 23$) and were divided into three categories, Graves' disease ($n = 4$), Hashimoto's disease ($n = 4$), and multinodular goiter ($n = 15$). Then, the samples were stored at $5-8^{\circ}\text{C}$ until use in the study.

For investigating IL-4 expression in tissues, the IL-4 primary antibody (catalog No.: E-AB-62102) from Elabsceince/China was used, and IHC staining was accomplished according to [22]. A semiquantitative method (Allred) was used to interpret IL-4 immunohistochemical staining [23].

The effect sample size of this was calculated depending on the Kish formula [24]:

$$n = \frac{Z^2 p(p-1)}{d^2} = \frac{(1.96)^2 \times 0.02(0.02-1)}{(0.05)^2} = 30.11 \quad [24]$$

Statistical analysis: SPSS software version 26 was used for data analysis, and the ANOVA table and *post hoc* general liner model (GLM) were used to test the significance between different means. The Pearson correlation and Chi-square were used to examine the association between category variables [25].

Results

The result showed that there was no significant difference ($p \leq 0.05$) in BMI between cancer patients and control subjects since the values were $25.383 \pm 5.39 \text{ kg/m}^2$ and $26.819 \pm 3.92 \text{ kg/m}^2$, respectively (fig. 1). At the same time, there was a significant difference ($p \leq 0.05$) in serum IL-4 (pg/ml) between thyroid cancer patients and control subjects, with the value of $360.693 \pm 241.493 \text{ pg/ml}$ and $278.609 \pm 82.729 \text{ pg/ml}$, respectively (fig. 2).

During the comparison of the IL-4 (pg/ml) level among diagnosis categories, the results showed a significance difference ($p \leq 0.05$) between thyroid cancer and multinodular goiter (MNG), since the value was $342.788 \pm 234 \text{ pg/ml}$ and $269.126 \pm 76.05 \text{ pg/ml}$ respectively. A higher serum IL-4 pg/ml level was observed in the Hashimoto thyroiditis group ($383.67 \pm 119.01 \text{ pg/ml}$) (tab. I).

There was a significant positive correlation ($r = 0.75$, $p = 0.013$) between serum level IL-4 (pg/ml) in thyroid cancer patients and BMI (kg/m^2). In contrast, the results of the Pearson correlation analysis in benign samples showed a negative correlation between serum level IL-4 and BMI (kg/m^2) ($r = -0.035$, $p = 0.756$) (fig. 3, 4).

For the histological study, all thyroid tissues were divided into two major groups of thyroid cancer and benign thyroid lesions, the benign thyroid tissues were divided into three categories, Graves' disease ($n = 4$), Hashimoto's ($n = 4$), and multinodular goiter ($n = 15$).

Thyroid cancer

The examination of thyroid cancer slides shows that all 36 samples (11 men and 25 women) belonged to papillary thyroid carcinoma, characterized by typical distinctive features. The tumor area and the normal thyroid parenchyma consists of different size follicles surrounded by normal thyroid cells filled with colloids separated by thin and thick capsules of collagen bundles, while the papillary tumor area is characterized by many papillary nuclear features, nuclear enlargement, nuclear clearing, and nuclear grooves, with multiple blood vessels (fig. 5).

In addition, another section of the papillary thyroid carcinoma shows papillary and follicular patterns, solid growth,




Figure 1. Distribution of BMI (kg/m²) in thyroid cancer and control subjects




Figure 2. Level of serum IL-4 (pg/ml) in thyroid cancer and control subjects

Table I. Level of IL-4 (pg/ml) in all subjects

Diagnosis		No.	Percent (%)	IL-4 (pg/ml) mean ± SD
cancer		25	24.03	342.788 ± 234 ^a
control group	hyperthyroidism	9	8.66	310.195 ± 65.035 ^{ab}
	hypothyroidism	2	1.93	324.082 ± 155.77 ^{ab}
	Graves	10	9.61	262.839 ± 133.376 ^{ab}
	MNG	54	51.92	269.126 ± 76.05 ^b
	Hashimoto	4	3.84	383.67 ± 119.01 ^{ab}

LSD – cancer × MNG = 73.66, $p = 0.046^*$, cancer × hyperthyroidism, $p = 0.523^{NS}$, cancer × hypothyroidism, $p = 0.822^{NS}$, cancer × Graves, $p = 0.338^{NS}$, cancer × Hashimoto, $p = 0.52^{NS}$. The mean difference is significant at $p \leq 0.05$. NS – non-significant at level $p \leq 0.05$




Figure 3. Correlation between IL-4 (pg/ml) level and BMI (kg/m²) in thyroid cancer samples




Figure 4. Correlation between IL-4 (pg/ml) level and BMI (kg/m²) in control samples

and micro follicles separated by collagen fibers. During high power magnification, there were many sites of capsular and vesicular invasion, with papillary nuclear features such as nuclear clearing, nuclear grooves, and inclusion bodies, in addition to many sites of vascular and capsular invasion by malignant cells inside the vascular space of the tumor capsule (fig. 6).

Semiquantitative detection of IL-4 in thyroid gland tissues by immunohistochemistry assay

The expression of IL-4 in the thyroid tissues of cancer patients was strong in 8 (22.22%) slides (total 36 slides), moderate in 7 (19.44%), weak in 8 (22.22%), and negative in 13 (36.11%), with no significant difference $p \leq 0.05$ between the two groups (cancer and control) (Chi-square 5.345, $p = 0.148$) (tab. II and fig. 7).




Figure 5. A section of the papillary thyroid carcinoma; (A) representative view showing a mixture of different size follicles black arrow (→) diffusely present papillary nuclear features cells (↗), follicles filled by colloid (pink color) (☆) and lined by normal-appearing cells (→), thick capsule (→); (B) shows papillary nuclear feature cells (↗), follicle growth pattern (→), capsule of collagen fibers (→) blood vessels also presented (→), (H&E); stain (40x). (C) and (D) section show enlarged and irregular nuclei (↗), nuclear groove (↔), and nuclear clearing (↗) with follicles growth pattern filled with colloid (pink color ☆) (H&E); stain 400x

The expression of IL-4 in the control group was strong in 7 slides (30.44%), moderate in 8 slides (34.79%), weak in 5 slides (21.74%), and negative in 3 slides (13.03%) (tab. II and fig. 8).

Discussion

Interleukins are immunoregulatory proteins secreted in response to several stimuli and play a vital role in cancer diseases as initiation, progression, and elimination [16]. IL-4 is an anti-inflammatory cytokine that regulates the immune response in normal health conditions and under cancers [26]. The present study demonstrates a significant difference in level of IL-4 in thyroid cancer patients than both control subjects and MNG groups, and these findings agree with Zivancevic-Simonovic et al. [27], who found that IL-4 level was higher in thyroid cancer patients than in control subjects. IL-4 is a potent immunosuppressive cytokine that has an important role in maintaining and proliferating cancer cells and helping them to escape from the immune system [20]. Safi et al. [28] found that a high level of IL-4 was associated with the reoccurrence of lung cancer, and Todaro et al. [29] found that IL-4 is required for the survival

and growth of thyroid cancer cells. Although thyroid cancer cells do not constitutively produce IL-4, our results support a thyroid cancer induce infiltrating cells to produce IL-4.

Z. Li et al. [30] suggested that endogenous IL-4, the product of host immune response, can be used by tumor cells to facilitate their growth. IL-4 might act as a pro tumoral agent [31]. On the other hand, IL-4 may have an antitumor role since it acts synergistically with interferon- γ to prime maturing antigen-presenting dendritic cells to produce high levels of a Th1 cytokine IL-12 that induces the differentiation of tumor-specific Th1-cells and cytotoxic T lymphocytes [32]. In contrast, previous studies indicate that although genetic variants in IL-4 do not affect the risk or outcome of differentiated thyroid cancer (DTC) patients, their influence on the behavior of thyroid tumors deserves further investigation [31]. Many studies reported a direct inhibitory effect of IL-4 on the growth of human gastric cancer, melanomas, spontaneous adenocarcinoma, fibrosarcoma, and renal cell carcinoma [17, 33–35].

The higher production of serum IL-4 in the present study was observed in the Hashimoto thyroiditis group. More-




Figure 6. Papillary thyroid carcinoma; (A) showing a papillary pattern (→) with solid growth pattern (●) and micro follicle pattern (→) separated by prominent collagen fibrosis tissue (⊕) H&E; stain 40x. (B) in high magnification view from the same section, H&E; stain 100x. (C) shows many sites of capsular invasion (⊥), nuclear clearing (▲), nuclear grooves (▼), and inclusion body (▼) (H&E; stain 400x. (D) shows vascular invasion (⊥) inside the vascular space (☆) of the tumor capsule, H&E stain; (100x) and a high-power picture in the left corner; stain 400x

Table II. The immunohistochemistry score of IL-4 in thyroid cancer and control tissues

Diagnosis	Immunohistochemistry score						person Chi-square	p value
		negative	weak	moderate	strong	total		
malignant	count	13	8	7	8	36	5.345	0.148 ^{N.S.}
	%	36.11%	22.22%	19.44%	22.22%	100%		
benign	count	3	5	8	7	23		
	%	13.03%	21.74%	34.79%	30.44%	100%		

N.S. – non-significant at level $p \leq 0.05$

over, Hashimoto's is an autoimmune disease characterized by infiltrating lymphocytes inside thyroid tissue [36]. Many studies have demonstrated that significant amounts of IL-4 are secreted by T cells, helper T lymphocyte type 2 (Th2), mast cells, eosinophils, and basophils [20, 37]. The high level of IL-4 in the Hashimoto thyroiditis group in our study was in response to the increasing number of lymph cells which have an essential role in the secretion of IL-4. Our results are in agreement with Zivancevic-Simonovic et al. [27] and Schuetz

et al. [38] since they have also found increased IL-4 production in patients with Hashimoto thyroiditis.

Because thyroid cancer is a rare disease and accounts for less than 1% of all cancer types in the human body [10], and the majority of thyroid cancer is papillary carcinoma [39], our study supports this finding (that the majority of thyroid cancer is papillary carcinoma) due to all the cancer samples belonging to papillary thyroid carcinoma, is the most prevalent type of thyroid cancer [40, 41], but we




Figure 7. Immunohistochemical expression of IL-4 in thyroid cancer tissues; (A) section showing a negative expression; (B) weak positive staining, a red arrow (→); (C) strong positive staining, (red arrow); (D) negative control of thyroid cancer tissue; stain 400x




Figure 8. Immunohistochemical expression of IL-4 in benign thyroid tissues; (A) positive staining, red arrow (→); (B) negative control of benign thyroid tissue; stain 1000x

did not record any other thyroid cancer type due to its rare prevalence.

The present study confirms that obesity was not associated with a prevalence of thyroid cancer, there was no significant difference in BMI between cancer patients and control subjects.

Obesity has become a widely prevalent global health problem [42]. It has been posited that obesity causes thyroid cancer [43–45]. Furthermore, a correlation between being

overweight and thyroid cancer is not widely accepted. A retrospective study of 4849 patients with thyroid nodules (3809 females and 1040 males) did not confirm the positive correlation between thyroid cancer and obesity [46]. A similar conclusion has been reported by Ramdass et al. [47], which concluded that there was no correlation between BMI and development of thyroid cancer clinicopathological features [48].

In a histological study of IL-4, the current study revealed that the tissue expression of interleukin did not correlate with

serum interleukin levels. A similar conclusion was reached by [49]. The results of IL-4 expression in the current study revealed no significant difference between thyroid cancer and the control groups. The expression of IL-4 was similar in both the control and thyroid cancer tissues. These findings are in agreement with de Oliveira et al. [50] which found that IL-4 regulates the immune system response, the expression of IL-4 in tissues is not engaged in the clinicopathology characteristics of cancer. However, many studies have investigated that IL-4 expression increases independently of the duration and severity of the disease, the expression of IL-4 has been detected in many tissues, in brain tissue and cerebral nuclei (in the lateral ventricle) in mice affected by *Angiostrongylus* (a parasitic infection) [51]. IL-4 expression was detected in the wounds on days 1 to 4 after wounding and then decreased progressively and disappeared on day 21 [52]. Abbas (2017) [54] showed that in cancer cachectic patients, IL-6 produces in large quantities which may be this trigger the different cells to release more cytokines.

Others have shown that expressing IL-4 in tissue improves the immune response against human ovarian melanoma, breast carcinoma [55], and thyroid cancer [20].

Conclusions

These findings indicate that serum levels of IL-4 may help diagnose thyroid cancer and identify patients with the active disease who deserve closer medical attention. Although thyroid cancer does not produce IL-4, it can induce other cells to produce IL-4. The tissue expression of interleukin did not correlate with serum interleukin levels. Furthermore, secretion of IL-4 was systematic and not localized in thyroid cancer tissues. Obesity was not associated with a prevalence of thyroid cancer.

Conflict of interest: none declared

Ali Reda Hussein

Basrah University

College of Sciences

Physiology, Biology Department

Ph.D. student

Basrah, Iraq

e-mail: ali_reada1984@yahoo.com

Received: 9 Feb 2023

Accepted: 31 Mar 2023

References

- Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. *CA Cancer J Clin.* 2007; 57(1): 43–66, doi: 10.3322/canjclin.57.1.43, indexed in Pubmed: 17237035.
- Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. *Crit Rev Oncog.* 2013; 18(1-2): 43–73, doi: 10.1615/critrevoncog.v18.i1-2.40, indexed in Pubmed: 23237552.
- Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. *Nat Rev Cancer.* 2002; 2(8): 563–572, doi: 10.1038/nrc865, indexed in Pubmed: 12154349.
- American Cancer Society. Cancer Facts & Figures 2021. Atlanta: 2021. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html>.

- Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid.* 2016; 26(1): 1–133, doi: 10.1089/thy.2015.0020, indexed in Pubmed: 26462967.
- Fallahi P, Mazzi V, Vita R, et al. New therapies for dedifferentiated papillary thyroid cancer. *Int J Mol Sci.* 2015; 16(3): 6153–6182, doi: 10.3390/ijms16036153, indexed in Pubmed: 25789503.
- Mironska A, Łukaszewicz-Zajac M, Mroczko B. Clinical Significance of Selected Chemokines in Thyroid Cancer. *Anticancer Res.* 2019; 39(6): 2715–2720, doi: 10.21873/anticancer.13397, indexed in Pubmed: 31177106.
- Zhang GQ, Shen CT, Song HJ, et al. High Expression of Interleukin-12A and Its Association with the Clinicopathology and Prognosis of Differentiated Thyroid Cancer. *Eur Thyroid J.* 2020; 9(3): 139–147, doi: 10.1159/000505811, indexed in Pubmed: 32523890.
- Karagiannis AK, Philippou A, Tseleni-Balafouta S, et al. IGF-IEc Expression Is Associated With Advanced Differentiated Thyroid Cancer. *Anticancer Res.* 2019; 39(6): 2811–2819, doi: 10.21873/anticancer.13409, indexed in Pubmed: 31177118.
- Guth S, Theune U, Aberle J, et al. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. *Eur J Clin Invest.* 2009; 39(8): 699–706, doi: 10.1111/j.1365-2362.2009.02162.x, indexed in Pubmed: 19601965.
- Bernet VJ, Chindris AM. Update on the Evaluation of Thyroid Nodules. *J Nucl Med.* 2021; 62(Suppl 2): 13S–19S, doi: 10.2967/jnuclmed.120.246025, indexed in Pubmed: 34230067.
- Al-Subaiee I, Al-Rikaby H. Prevalence of thyroid incidentaloma detected by high-resolution ultrasound and their potential risk of malignancy in healthy individuals in Basrah Province. *Medical Journal of Babylon.* 2019; 16(3): 252, doi: 10.4103/mjbl.mjbl_31_19.
- Mansour A, Alhamza AA, Almomin AA, et al. SUN-418 Patterns of Thyroid Disease in Basrah, Iraq. Retrospective Study. *Journal of the Endocrine Society.* 2020; 4(Supplement_1), doi: 10.1210/jendso/bvaa046.772.
- Liu H, Lin F. Application of immunohistochemistry in thyroid pathology. *Arch Pathol Lab Med.* 2015; 139(1): 67–82, doi: 10.5858/arpa.2014-0056-RA, indexed in Pubmed: 25549145.
- Martins MB, Marcello MA, Batista Fd, et al. Serum interleukin measurement may help identify thyroid cancer patients with active disease. *Clin Biochem.* 2018; 52: 1–7, doi: 10.1016/j.clinbiochem.2017.10.003, indexed in Pubmed: 28987791.
- Holder PG, Lim SA, Huang CS, et al. Engineering interferons and interleukins for cancer immunotherapy. *Adv Drug Deliv Rev.* 2022; 182: 114112, doi: 10.1016/j.addr.2022.114112, indexed in Pubmed: 35085624.
- Hoon DS, Banez M, Okun E, et al. Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. *Cancer Res.* 1991; 51(8): 2002–2008, indexed in Pubmed: 1901239.
- Cunha LL, Morari EC, Nonogaki S, et al. Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer. *Cancer Immunol Immunother.* 2017; 66(2): 141–148, doi: 10.1007/s00262-016-1924-4, indexed in Pubmed: 27858102.
- Xi C, Zhang GQ, Sun ZK, et al. Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice. *Front Immunol.* 2020; 11: 1124, doi: 10.3389/fimmu.2020.01124, indexed in Pubmed: 32655554.
- Vella V, Mineo R, Frasca F, et al. Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease. *J Clin Endocrinol Metab.* 2004; 89(6): 2880–2889, doi: 10.1210/jc.2003-031639, indexed in Pubmed: 15181072.
- NIH. National Heart, Lung and Blood Institute. Calculate the Body Mass Index. 2022. https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm.
- Immunohistochemistry and Immunocytochemistry: Essential Methods. 2017, doi: 10.1002/9781118717769.
- Choudhury KR, Yagle KJ, Swanson PE, et al. A robust automated measure of average antibody staining in immunohistochemistry images. *J Histochem Cytochem.* 2010; 58(2): 95–107, doi: 10.1369/jhc.2009.953554, indexed in Pubmed: 19687472.
- Rao J, Kish L. Survey Sampling. *Biometrics.* 1969; 25(3): 603, doi: 10.2307/2528920.
- IBM. IBM SPSS Advanced Statistics 24. 2019.
- Suzuki A, Leland P, Joshi BH, et al. Targeting of IL-4 and IL-13 receptors for cancer therapy. *Cytokine.* 2015; 75(1): 79–88, doi: 10.1016/j.cyt.2015.05.026, indexed in Pubmed: 26088753.

27. Zivancevic-Simonovic S, Mihaljevic O, Majstorovic I, et al. Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis. *Cancer Immunol Immunother*. 2015; 64(8): 1011–1019, doi: 10.1007/s00262-015-1705-5, indexed in Pubmed: 25971541.
28. Safi S, Yamauchi Y, Hoffmann H, et al. Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-Naïve Patients with Resectable Non-Small-Cell Lung Cancer. *Cancers (Basel)*. 2020; 12(12), doi: 10.3390/cancers12123496, indexed in Pubmed: 33255425.
29. Todaro M, Zerilli M, Ricci-Vitiani L, et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. *Cancer Res*. 2006; 66(3): 1491–1499, doi: 10.1158/0008-5472.CAN-05-2514, indexed in Pubmed: 16452205.
30. Li Z, Jiang J, Wang Z, et al. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. *Cancer Res*. 2008; 68(21): 8687–8694, doi: 10.1158/0008-5472.CAN-08-0449, indexed in Pubmed: 18974110.
31. Martins MB, de Assis Batista F, Bufalo NE, et al. Polymorphisms of IL-4 and IL-4R are associated to some demographic characteristics of differentiated thyroid cancer patients but are not determinants of risk in the Brazilian population. *Endocrine*. 2021; 72(2): 470–478, doi: 10.1007/s12020-020-02486-z, indexed in Pubmed: 32902809.
32. Giermasz AS, Urban JA, Nakamura Y, et al. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. *Cancer Immunol Immunother*. 2009; 58(8): 1329–1336, doi: 10.1007/s00262-008-0648-5, indexed in Pubmed: 19156413.
33. Eguchi J, Kuwashima N, Hatano M, et al. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. *J Immunol*. 2005; 174(11): 7194–7201, doi: 10.4049/jimmunol.174.11.7194, indexed in Pubmed: 15905564.
34. Noffz G, Qin Z, Kopf M, et al. Neutrophils but Not Eosinophils Are Involved in Growth Suppression of IL-4-Secreting Tumors. *J Immunol*. 1998; 160(1): 345–350, doi: 10.4049/jimmunol.160.1.345, indexed in Pubmed: 9551990.
35. Street NE, Mosmann TR. IL4 and IL5: the role of two multifunctional cytokines and their place in the network of cytokine interactions. *Biotherapy*. 1990; 2(4): 347–362, doi: 10.1007/BF02170084, indexed in Pubmed: 2268500.
36. Colledge NR, Walker BR, Ralston SH. Davidson 's Principles and Practice of Medicine, 21st ed. Edinburgh Churchill Livingstone/Elsevier, London 2010.
37. Thomson AW, Lotze MT. The Cytokine Handbook, 4 ed., vol. I. Elsevier 2003.
38. Schuetz M, Duan H, Wahl K, et al. T lymphocyte cytokine production patterns in Hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. *Anticancer Res*. 2006; 26(6B): 4591–4596, indexed in Pubmed: 17201182.
39. Mustafa MA, Malenie R, Mir F, et al. Malignant effusions secondary to metastatic thyroid carcinomas: A review of 15 cases. *Cancer Cytopathol*. 2023; 131(2): 136–143, doi: 10.1002/cncy.22654, indexed in Pubmed: 36219535.
40. Al-Atrooshi SAM, Ibraheem NH, Yahya TT. The Prevalence of Papillary Thyroid Microcarcinoma in 489 Cases of Thyroidectomy in Iraqi Patients. *Iraqi Postgraduate Medical Journal*. 2017; 16(2): 151–158.
41. Kadhim A, Kadhim MA, Ahmed BS, et al. The frequency of thyroid carcinoma in patients with solitary and multiple nodules utilizing ultrasound guided fine needle aspiration cytology (FNAC): A prospective study (Thyroid carcinoma and U / S guided FNA). *J Fac Med Baghdad*. 2010; 52(2): 134–138.
42. NHLBI. Managing Overweight and Obesity in Adults: Systematic Evidence Review from the Obesity Expert Panel. 2021: 501. <https://www.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-review.pdf>.
43. Han JiM, Kim TY, Jeon MJi, et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. *Eur J Endocrinol*. 2013; 168(6): 879–886, doi: 10.1530/EJE-13-0065, indexed in Pubmed: 23513231.
44. Masone S, Velotti N, Savastano S, et al. Morbid Obesity and Thyroid Cancer Rate. A Review of Literature. *J Clin Med*. 2021; 10(9): 1894, doi: 10.3390/jcm10091894, indexed in Pubmed: 33925549.
45. He Q, Sun H, Li F, et al. Obesity and risk of differentiated thyroid cancer: A large-scale case-control study. *Clin Endocrinol (Oxf)*. 2019; 91(6): 869–878, doi: 10.1111/cen.14091, indexed in Pubmed: 31479527.
46. Rotondi M, Castagna MG, Cappelli C, et al. Obesity Does Not Modify the Risk of Differentiated Thyroid Cancer in a Cytological Series of Thyroid Nodules. *Eur Thyroid J*. 2016; 5(2): 125–131, doi: 10.1159/000445054, indexed in Pubmed: 27493887.
47. Ramdass V, Caskey E, Sklarz T, et al. Association Between Obesity and Cancer Mortality: An Internal Medicine Outpatient Clinic Perspective. *J Clin Med Res*. 2021; 13(7): 377–386, doi: 10.14740/jocmr4543, indexed in Pubmed: 34394780.
48. Gąsior-Perczak D, Pałyga I, Szymonek M, et al. The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer. *PLoS One*. 2018; 13(10): e0204668, doi: 10.1371/journal.pone.0204668, indexed in Pubmed: 30273371.
49. Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. *Anticancer Res*. 2006; 26(5B): 3905–3911, indexed in Pubmed: 17094421.
50. de Oliveira MV, Fraga CA, Gomez RS, et al. Immunohistochemical expression of interleukin-4, -6, -8, and -12 in inflammatory cells in surrounding invasive front of oral squamous cell carcinoma. *Head Neck*. 2009; 31(11): 1439–1446, doi: 10.1002/hed.21121, indexed in Pubmed: 19424975.
51. Wang TY, Chen KY, Jhan KY, et al. Temporal-spatial expressions of interleukin-4, interleukin-10, and interleukin-13 in the brains of C57BL/6 and BALB/c mice infected with *Angiostrongylus cantonensis*: An immunohistochemical study. *J Microbiol Immunol Infect*. 2020; 53(4): 592–603, doi: 10.1016/j.jmii.2018.10.010, indexed in Pubmed: 30600200.
52. Salmon-Ehr V, Ramont L, Godeau G, et al. Implication of interleukin-4 in wound healing. *Lab Invest*. 2000; 80(8): 1337–1343, doi: 10.1038/labinvest.3780141, indexed in Pubmed: 10950124.
53. Abbas EK. Molecular and gene expression study of interleukin-6 (IL-6) in patients with cancer cachexia syndrome. *Basrah*. 2017.
54. Suker DK, Badran AI, Abbas EK, et al. Immunohistochemistry Analysis for Interleukin-6 Expression from the Tumor Tissue. *International Journal of Sciences*. 2017; 3(03): 14–24, doi: 10.18483/ijsci.1198.
55. Obiri NI, Siegel JP, Varricchio F, et al. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. *Clin Exp Immunol*. 1994; 95(1): 148–155, doi: 10.1111/j.1365-2249.1994.tb06029.x, indexed in Pubmed: 8287600.